Your browser doesn't support javascript.
loading
Presence and Relevance of Myocardial Bridge in LAD-PCI of CTO and Non-CTO Lesions.
Yamamoto, Kei; Sugizaki, Yoichiro; Karmpaliotis, Dimitri; Sato, Takao; Matsumura, Mitsuaki; Narui, Shuro; Yamamoto, Myong Hwa; Fall, Khady N; James, Elizabeth I; Glinski, John B; Rabban, Maya L; Prasad, Megha; Ng, Vivian G; Sethi, Sanjum S; Nazif, Tamim M; Parikh, Sahil A; Vahl, Torsten P; Ali, Ziad A; Rabbani, LeRoy E; Collins, Michael B; Leon, Martin B; McEntegart, Margaret; Moses, Jeffrey W; Kirtane, Ajay J; Ochiai, Masahiko; Mintz, Gary S; Maehara, Akiko.
Affiliation
  • Yamamoto K; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Sugizaki Y; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Karmpaliotis D; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey, USA.
  • Sato T; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Matsumura M; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Narui S; Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
  • Yamamoto MH; Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
  • Fall KN; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • James EI; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Glinski JB; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Rabban ML; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Prasad M; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Ng VG; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Sethi SS; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Nazif TM; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Parikh SA; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Vahl TP; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Ali ZA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; St. Francis Hospital, Roslyn, New York, New York, USA.
  • Rabbani LE; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Collins MB; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA.
  • Leon MB; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • McEntegart M; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Moses JW; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; St. Francis Hospital, Roslyn, New York, New York, USA.
  • Kirtane AJ; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Ochiai M; Division of Cardiology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
  • Mintz GS; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA.
  • Maehara A; Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, New York, USA; Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA. Electronic address: amaehara@crf.org.
JACC Cardiovasc Interv ; 17(4): 491-501, 2024 Feb 26.
Article in En | MEDLINE | ID: mdl-38340105
ABSTRACT

BACKGROUND:

Intravascular ultrasound (IVUS) studies show that one-quarter of left anterior descending (LAD) arteries have a myocardial bridge. An MB may be associated with stent failure when the stent extends into the MB.

OBJECTIVES:

The aim of this study was to investigate 1) the association between an MB and chronic total occlusion (CTO) in any LAD lesions; and 2) the association between an MB and subsequent clinical outcomes after percutaneous coronary intervention in LAD CTOs.

METHODS:

A total of 3,342 LAD lesions with IVUS-guided percutaneous coronary intervention (280 CTO and 3,062 non-CTO lesions) were included. The primary outcome was target lesion failure (cardiac death, target vessel myocardial infarction, definite stent thrombosis, and ischemic-driven target lesion revascularization).

RESULTS:

An MB by IVUS was significantly more prevalent in LAD CTOs than LAD non-CTOs (40.4% [113/280] vs 25.8% [789/3,062]; P < 0.0001). The discrepancy in CTO length between angiography and IVUS was greater in 113 LAD CTOs with an MB than 167 LAD CTOs without an MB (6.0 [Q1, Q3 0.1, 12.2] mm vs 0.2 [Q1, Q3 -1.4, 8.4] mm; P < 0.0001). Overall, 48.7% (55/113) of LAD CTOs had a stent that extended into an MB after which target lesion failure was significantly higher compared to a stent that did not extend into an MB (26.3% vs 0%; P = 0.0004) or compared to an LAD CTO without an MB (26.3% vs 9.6%; P = 0.02).

CONCLUSIONS:

An MB was more common in LAD CTO than non-CTO LAD lesions. If present, approximately one-half of LAD CTOs had a stent extending into an MB that, in turn, was associated with worse outcomes.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Occlusion / Percutaneous Coronary Intervention / Myocardial Infarction Limits: Humans Language: En Journal: JACC Cardiovasc Interv Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Occlusion / Percutaneous Coronary Intervention / Myocardial Infarction Limits: Humans Language: En Journal: JACC Cardiovasc Interv Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2024 Type: Article Affiliation country: United States